Option Care Health (OPCH) to Release Quarterly Earnings on Wednesday

Option Care Health (NASDAQ:OPCH) will announce its earnings results before the market opens on Wednesday, October 30th. Analysts expect the company to announce earnings of $0.31 per share for the quarter. Option Care Health has set its FY 2024 guidance at EPS.Investors interested in listening to the company’s conference call can do so using this link.

Option Care Health (NASDAQ:OPCH) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.03. Option Care Health had a net margin of 4.60% and a return on equity of 14.82%. The company had revenue of $1.23 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the firm posted $0.63 EPS. The business’s revenue was up 14.8% compared to the same quarter last year. On average, analysts expect Option Care Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Option Care Health Stock Down 1.0 %

NASDAQ OPCH opened at $29.45 on Monday. Option Care Health has a twelve month low of $26.11 and a twelve month high of $34.63. The stock has a market cap of $5.12 billion, a PE ratio of 19.38, a PEG ratio of 2.31 and a beta of 1.29. The firm has a 50-day simple moving average of $31.00 and a 200 day simple moving average of $30.07. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.36 and a current ratio of 1.76.

Insider Buying and Selling at Option Care Health

In other Option Care Health news, Director Elizabeth Quadros Betten sold 47,531 shares of the company’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $31.09, for a total value of $1,477,738.79. Following the sale, the director now directly owns 21,339 shares in the company, valued at $663,429.51. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CFO Michael H. Shapiro sold 23,217 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $30.95, for a total transaction of $718,566.15. Following the completion of the sale, the chief financial officer now owns 247,317 shares of the company’s stock, valued at approximately $7,654,461.15. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Elizabeth Quadros Betten sold 47,531 shares of the business’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $31.09, for a total value of $1,477,738.79. Following the completion of the transaction, the director now directly owns 21,339 shares in the company, valued at $663,429.51. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.64% of the company’s stock.

Analysts Set New Price Targets

OPCH has been the subject of a number of research reports. JMP Securities raised their price objective on Option Care Health from $36.00 to $37.00 and gave the stock a “market outperform” rating in a research report on Monday, September 30th. Barrington Research reiterated an “outperform” rating and set a $40.00 price target on shares of Option Care Health in a research note on Wednesday, October 23rd.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.